You have everything: signed master research agreement with Cambridge biotech firm, detailed milestone schedule, monthly deliverable reports with principal investigator signatures, invoice approval emails from the Boston procurement director, FDA submission documentation showing your contracted research contributions. All documented. All accepted. All scientifically validated. 108 days overdue. Your Kendall Square contact's latest response? "Legal and compliance conducting routine contract review before authorizing final payment for this phase." The eighth time you've heard about this "routine" review.
The invoice references an LLC in Cambridge (Kendall Square biotech cluster), but they redirect you to their Boston financial operations office. Boston says Worcester manufacturing facility handles vendor payments for research contracts. Worcester redirects back to Cambridge research administration. Location confusion across Massachusetts (Cambridge innovation center vs Boston financial hub vs Worcester manufacturing)—and your invoice sits in legal review limbo while they continue research phases with your deliverables actively cited in ongoing FDA submissions and investor presentations.
They've gone silent for 108 days, and you're not sure if this is legitimate biotech/pharma compliance review (FDA-regulated research really does require extensive legal scrutiny), venture capital funding volatility (Series B round that may not close), Cambridge vs Boston organizational confusion, Massachusetts' sophisticated biotech market creating multi-layer approval chains, or whether escalation in Massachusetts' tight innovation ecosystem damages future opportunities where the same investors, researchers, and executives cycle across every Kendall Square startup.
If This Sounds Familiar, You're in the Right Place
- Net 30-45 terms routinely drift to Net 75-150+ with "legal review" or "compliance approval pending" responses in biotech/pharma bureaucracy
- Acceptance disputes appear only after payment requests (research milestone completion, pharmaceutical specifications, software development sprints)
- Entity confusion: Cambridge Kendall Square vs Boston financial operations vs Worcester manufacturing (nobody owns the invoice across Massachusetts regions)
- Decision-maker who approved is now "legal department reviewing" or "Series [X] funding pending" and research contact won't make payment decisions
- Evidence scattered: master research agreements, milestone reports, deliverable documentation, FDA submission records across biotech and pharma systems
- Venture capital funding: "Series B closing soon" or "investor wire expected" creates indefinite delays in Cambridge/Boston startup ecosystem
- Cross-state complications: you're outside Massachusetts, unfamiliar with Boston biotech culture and Cambridge innovation ecosystem dynamics
- Cambridge vs Boston vs Route 128: biotech research vs financial services vs tech corridor—different business cultures and payment paces
What Changes When Collecty Runs the File
- Evidence pack assembled in first 48 hours — master agreements, milestone reports, deliverables, acceptance emails, FDA documentation—biotech/pharma standards met
- Entity and decision-owner mapping — who approves payments in Cambridge, Boston, Worcester—biotech funding or pharma procurement structure traced
- Industry-aware outreach — we work with biotech, pharma, tech, financial services—understanding Massachusetts innovation realities and FDA compliance requirements
- Acceptance reconstruction — when "legal review" or "milestone completion" disputes appear
- Massachusetts-aware escalation routing — state court procedures, judgment enforcement, balance between relationship preservation and formal action
- Documented reporting cadence — you know what's happening through funding rounds and compliance cycles
Collecty works Massachusetts B2B files from $5K to $2M+, across biotechnology, pharmaceuticals, technology, and financial services—evidence-first, Massachusetts-aware across Boston, Cambridge, Worcester, Springfield, and Lowell.
The Massachusetts Innovation Protocol™
The Massachusetts Innovation Protocol™ analyzes contract type and state court enforcement options early, maps Massachusetts entity and region-based decision ownership (Boston/Cambridge biotech hub, Route 128 tech corridor), reconstructs acceptance across industries (biotech, pharma, tech, financial services), routes escalation with Massachusetts court compliance while understanding venture capital funding volatility and pharmaceutical procurement cycles, and documents every step in English for cross-state transparency.
How We Work Massachusetts B2B Files
Evidence Pack Intake + Massachusetts Compliance Check
Master agreements, milestone reports, FDA documentation gathered. Massachusetts statute of limitations verified (6 years written contracts). Biotech/pharma documentation organized.
Entity + Decision-Owner Mapping
Cambridge Kendall Square vs Boston finance vs Worcester manufacturing traced. Actual payment authority identified—biotech funding structure or corporate approval chain.
Industry-Aware Outreach
Biotech funding cycles understood. FDA compliance timing respected. Innovation ecosystem culture-appropriate communication deployed.
Acceptance/Milestone Reconstruction
When "legal review" or "milestone disputes" appear after payment requests, documented acceptance evidence assembled.
Massachusetts Court Escalation + Reporting
State court procedures, judgment enforcement, relationship-smart escalation in tight innovation ecosystem. Clear timeline throughout.
Massachusetts Industries We Serve
🧬 Biotechnology & Pharmaceuticals
Research milestones, clinical trial services, FDA submission support across Cambridge Kendall Square and Boston biotech corridor.
đź’» Technology & Software
Route 128 tech corridor services, SaaS implementations, development contracts across Massachusetts' technology sector.
đź’° Financial Services
Investment management services, fintech contracts, professional services across Boston's financial hub (Fidelity, State Street).
🎓 Higher Education B2B
University vendor contracts, research institution services, equipment supply across Harvard, MIT, and academic networks.
🏥 Healthcare Services B2B
Medical equipment, hospital services, research contracts across Boston, Cambridge, and regional healthcare systems.
🤖 Robotics & AI
Automation systems, AI development services, robotics contracts across Massachusetts' emerging tech sectors.
Massachusetts Legal Framework
Frequently Asked Questions
Sarah Lindberg
International Operations Lead
Sarah coordinates our global partner network across 160+ countries, ensuring seamless cross-border debt recovery.
